292 related articles for article (PubMed ID: 24882577)
1. Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.
Elias D; Vever H; Lænkholm AV; Gjerstorff MF; Yde CW; Lykkesfeldt AE; Ditzel HJ
Oncogene; 2015 Apr; 34(15):1919-27. PubMed ID: 24882577
[TBL] [Abstract][Full Text] [Related]
2. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer.
Joshi T; Elias D; Stenvang J; Alves CL; Teng F; Lyng MB; Lykkesfeldt AE; Brünner N; Wang J; Gupta R; Workman CT; Ditzel HJ
Oncotarget; 2016 Aug; 7(35):57239-57253. PubMed ID: 27528030
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells.
Men X; Su M; Ma J; Mou Y; Dai P; Chen C; Cheng XA
Technol Cancer Res Treat; 2021; 20():15330338211004916. PubMed ID: 33745390
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
[TBL] [Abstract][Full Text] [Related]
6. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
Jan R; Huang M; Lewis-Wambi J
Breast Cancer Res; 2012 Nov; 14(6):R146. PubMed ID: 23151593
[TBL] [Abstract][Full Text] [Related]
7. Altered radiation responses of breast cancer cells resistant to hormonal therapy.
Luzhna L; Lykkesfeldt AE; Kovalchuk O
Oncotarget; 2015 Jan; 6(3):1678-94. PubMed ID: 25682200
[TBL] [Abstract][Full Text] [Related]
8. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
9. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
10. Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.
Wu X; Zahari MS; Renuse S; Nirujogi RS; Kim MS; Manda SS; Stearns V; Gabrielson E; Sukumar S; Pandey A
Mol Cell Proteomics; 2015 Nov; 14(11):2887-900. PubMed ID: 26330541
[TBL] [Abstract][Full Text] [Related]
11. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen.
Maraqa L; Cummings M; Peter MB; Shaaban AM; Horgan K; Hanby AM; Speirs V
Clin Cancer Res; 2008 Jan; 14(2):405-11. PubMed ID: 18223215
[TBL] [Abstract][Full Text] [Related]
12. WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206.
Ren YQ; Wang HJ; Zhang YQ; Liu YB
Cancer Chemother Pharmacol; 2017 May; 79(5):1003-1011. PubMed ID: 28391353
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
14. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
15. MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM.
Chen MJ; Cheng YM; Chen CC; Chen YC; Shen CJ
Biochem Biophys Res Commun; 2017 Feb; 483(2):840-846. PubMed ID: 28063929
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
[TBL] [Abstract][Full Text] [Related]
17. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
[TBL] [Abstract][Full Text] [Related]
18. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
Xiong H; Jin X; You C
Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
[TBL] [Abstract][Full Text] [Related]
19. Elevated Hexokinase II Expression Confers Acquired Resistance to 4-Hydroxytamoxifen in Breast Cancer Cells.
Liu X; Miao W; Huang M; Li L; Dai X; Wang Y
Mol Cell Proteomics; 2019 Nov; 18(11):2273-2284. PubMed ID: 31519767
[TBL] [Abstract][Full Text] [Related]
20. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]